Bernstein: Weekend Healthcare Pulse — Are CNPVs Really Faster?
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
Bernstein examines whether the FDA's new Commissioner's National Priority Voucher (CNPV) pathway genuinely accelerates drug approvals. While the CNPV aims to condense review timelines to just one to two months, real-world execution remains uncertain. As of January 2026, the FDA has granted 18 CNPVs, yet only one drug has been approved—a previously marketed generic aimed at supporting US manufacturing.
Recent reports indicate that several CNPU PDUFA dates have slipped by weeks or months. For instance, Eli Lilly's Orforglipron was delayed from March 28 to April 10. Sanofi's Tzield and Ironwood's Bitopertin also faced delays due to safety and efficacy concerns. Bernstein estimates that novel new drug applications are unlikely to clear review within one to two months; a more realistic baseline is around four months. Supplemental applications for new indications might move faster, though this heavily depends on data quality.
The report contextualizes CNPV against standard 10-month and priority 6-month reviews. Historically, the FDA has not always met target timelines, subject to Parkinson's Law where work expands to fill available time. Furthermore, the vaguely defined and potentially political selection criteria for CNPVs elevate legal risks, as abbreviated review timelines could lead to oversight errors. Ultimately, CNPVs offer speed, but significant regulatory and procedural bottlenecks persist.